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ABSTRACT
Epstein-Barr virus (EBV) encodes BPLF1, a lytic cycle protein with deubiquitinating activity that is contained in its N-terminal
domain and conserved across the Herpesviridae. EBV replication is associated with cellular DNA replication and repair factors,
and initiation of EBV lytic replication induces a DNA damage response, which can be regulated at least in part by BPLF1. The
cellular DNA repair pathway, translesion synthesis (TLS), is disrupted by BPLF1, which deubiquitinates the DNA processivity
factor, PCNA, and inhibits the recruitment of the TLS polymerase, polymerase eta (Pol eta), after damage to DNA by UV irradia-
tion. Here we showed that the E3 ubiquitin ligase, which activates TLS repair by monoubiquitination of PCNA, is also affected by
BPLF1 deubiquitinating activity. First, BPLF1 interacts directly with Rad18, and overexpression of BPLF1 results in increased
levels of the Rad18 protein, suggesting that it stabilizes Rad18. Next, expression of functionally active BPLF1 caused relocaliza-
tion of Rad18 into nuclear foci, which is consistent with sites of cellular DNA replication that occur during S phase. Also, levels
of Rad18 remain constant during lytic reactivation of wild-type virus, but reactivation of BPLF1 knockout virus resulted in de-
creased levels of Rad18. Finally, the contribution of Rad18 levels to infectious virus production was examined with small inter-
fering RNA (siRNA) targeting Rad18. Results demonstrated that reducing levels of Rad18 decreased production of infectious
virus, and infectious titers of BPLF1 knockout virus were partially restored by overexpression of Rad18. Thus, BPLF1 interacts
with and maintains Rad18 at high levels during lytic replication, which assists in production of infectious virus.
IMPORTANCE
Characterization of EBV BPLF1’s deubiquitinating activity and identification of its targets and subsequent functional effects
remain little studied. All members of the Herpesviridae contain BPLF1 homologs with conserved enzymatic activity, and find-
ings discovered with EBV BPLF1 are likely applicable to other members of the family. Discovery of new targets of BPLF1 will
point to cellular pathways and viral processes regulated by the enzymatic activity of the EBV-encoded deubiquitinating enzyme.
Here we determined the importance of the cellular ubiquitin ligase Rad18 in these processes and how it is affected by BPLF1. Our
findings demonstrate that EBV can co-opt Rad18 as a novel accessory factor in the production of infectious virus.
Epstein-Barr virus (EBV), a human herpesvirus, is one of themost common human viruses, infecting more than 90% of
people worldwide. EBV is transmitted through saliva and initially
infects the epithelial cells in the oropharyngeal cavity (1–3). As the
initial lytic infection is brought under control, EBV, as do all
members of the herpesviridae, establishes lifelong latency in sec-
ondary target cells, which in the case of EBV are memory B lym-
phocytes (1, 4). There are three types of EBV latency: I, II, and III,
each characterized by expression of a limited set of viral RNAs and
gene products. EBV latency types are associated with several dis-
tinct malignancies, including immunoblastic lymphomas (type
III), Hodgkin lymphoma (type II), and Burkitt lymphoma (type
I), as well as nasopharyngeal carcinoma (type II) (5–7). Latent
virus can be reactivated periodically into the lytic state, with pro-
duction of virus, which is asymptomatic except in persons with
acquired or inborn immunodeficiency. Both during initial infec-
tion and after reactivation of the lytic cycle, the full complement of
approximately 90 lytic proteins is expressed. Infectious mono-
nucleosis is the classic disease caused by EBV lytic infection as
a result of primary infection during adolescence and young
adult years (8).
BPLF1 is the largest EBV protein (3,149 amino acids) and is
expressed late in the lytic cycle. However, BPLF1 and its herpesvi-
ral homologs can function both early and late in viral infection,
since the proteins are located in the tegument, and mRNA levels
are detected as early as 6 to 8 h after infection (9–13). BPLF1 has
deubiquitinating (DUB) as well as deneddylase activity expressed
from its N-terminal domain (14–16). Both enzymatic activities
are localized to a catalytic triad, composed of a His, Asp, and Cys
residue, that is strictly conserved across the herpesvirus family.
Mutation of the catalytic triad results in loss of both deubiquiti-
nating and deneddylating activities (16–19). EBV BPLF1 knock-
out virus, as well as knockout of herpesvirus homolog genes, re-
sults in loss of infectivity (typically 90%) and/or reduces genome
copy numbers (17, 20–24). BPLF1 has been shown to block pro-
teasomal degradation of cytosolic and endoplasmic reticulum
proteins by removal of ubiquitin from targeted substrates (25).
Several major targets have been identified for BPLF1 deubiquiti-
nating activity. The first identified was the large subunit of EBV
ribonucleotide reductase, deubiquitination of which downregu-
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lates viral ribonucleotide reductase activity; this is the only viral
target identified to date (17). We have also found that BPLF1
deubiquitinates the cellular processivity factor, PCNA, the first
cellular target identified for BPLF1 deubiquitinating activity, and
inhibits the DNA repair process, translesion synthesis (TLS), after
UV damage (26). Saito et al. demonstrated that BPLF deubiquiti-
nates TRAF6, which can inhibit NF-B signaling during lytic
infection (24). The Kaposi’s sarcoma-associated herpesvirus
(KSHV) homolog, Orf64, was shown to decrease RIG-I ubiquiti-
nation and reduce RIG-I-mediated interferon (IFN) signaling
(27). The deneddylase activity of BPLF1 has been implicated in
modulating the activity of cullin-RING ligases (16, 28). These var-
ious findings demonstrate important roles for BPLF1 and poten-
tially its homologs in viral replication and infectivity.
Seven lytic gene products have been identified as necessary and
sufficient for replication of EBV at oriLyt: BZLF1 (the EBV imme-
diate early transactivator), BALF5 (DNA polymerase), BMRF1
(DNA processivity factor), BALF2 (single-stranded DNA binding
protein), BBLF4 (helicase), BSLF1 (primase), and BBLF2/3 (heli-
case-primase accessory protein) (29–36). While EBV encodes its
own proteins that are sufficient for viral DNA replication in vitro,
many cellular DNA replication and repair proteins that regulate
and enhance viral replication in vivo are associated with viral DNA
replication. For example, the EBV DNA polymerase, BALF5, is
dependent on chaperone Hsp90 for its localization to the nucleus
(37). Kudoh et al. showed that many homologous recombina-
tional repair factors, including Rad51, Rad52, RPA, and the MRN
complex (MRE11-RAD50-NBS1), are located in replication com-
plexes and are loaded onto newly synthesized viral genomes, im-
plicating them in viral DNA synthesis (38). Additionally, the mis-
match repair proteins MSH2, MSh6, MLH1, and PMS2, along
with PCNA and the PCNA clamp-loader complex, are also local-
ized to EBV replication compartments (39). Homologous recom-
bination factors and the MRN complex have also been detected in
replication compartments of other members of the herpesviridae
(40–45). Our recent work identified TLS repair factors that are
also associated with EBV and are specifically affected by the deu-
biquitinating activity of BPLF1 (26). PCNA, which is loaded onto
viral DNA during EBV DNA replication (39), is monoubiquiti-
nated in response to DNA damage and initiates postreplication
repair (PRR) through recruitment of the specialized TLS polymer-
ase, polymerase eta (Pol eta), to the site of damage. Deubiquitina-
tion of PCNA by BPLF1 abolishes recruitment of pol eta to sites of
DNA damage, resulting in inhibition of TLS (26). Here we report
on the contributions of the TLS factor Rad18, which is engaged
and modulated by BPLF1.
Rad18 (the E3 ubiquitin-ligating enzyme) is part of the E2/E3
ubiquitin complex and is responsible for monoubiquitination of
PCNA, which initiates several cellular DNA repair processes (46–
50). Rad18 forms a complex with the E2 ubiquitin-conjugating
enzyme Rad6 through a conserved RING finger motif (51). Ubiq-
uitin is activated by the E1 ubiquitin-activating enzyme, Ube1, in
an ATP-dependent fashion and transfers ubiquitin to the active
site cysteine. E2 catalyzes the transfer of ubiquitin from the active
site of E1 to the active site of E2. The E3 ubiquitin-ligating enzyme
then transfers the ubiquitin through an isopeptide bond that typ-
ically links a lysine residue of the target protein to the C-terminal
glycine of ubiquitin.
Given that Rad18 monoubiquitinates PCNA, is a member of
the TLS DNA damage response pathway, and is itself ubiquiti-
nated, we set out to determine if BPLF1 could directly affect Rad18
ubiquitination and confer a role for Rad18 in the EBV life cycle.
Here we report that BPLF1 interacts with the E2/E3 ubiquitin
complex (Rad6/18), upregulates Rad18 protein levels, and reorga-
nizes Rad18 into focus-forming units in the nucleus. Finally, we
have shown that Rad18 is important for efficient production of
infectious virus. Thus, these findings uncover a new function for
this cellular ubiquitin E3 ligase and its likely important accessory
role in EBV replication and infectivity in the viral life cycle. In light
of the conserved nature of the herpesvirus deubiquitinating en-
zymes, observations on the role of Rad18 in EBV infection are
likely to extend to other members of the herpesviridae family.
MATERIALS AND METHODS
Cell line, growth, and transfection. The H1299, 293T, 293EBV, and
293EBV BPLF1 knockout cell lines (kindly provided by T. Tsurumi
[24]) were cultured in Dulbecco’s modified Eagle medium (DMEM) sup-
plemented with 10% fetal bovine serum and antibiotics (26). Lipo-
fectamine 2000 (Invitrogen) and Effectene (Qiagen) were used for trans-
fections according to the manufacturer’s protocol.
Antibodies, immunoprecipitations, and immunoblotting. FLAG-
tagged BPLF1 (17) was immunoprecipitated with FLAG M2 antibody
bound to magnetic Dynabeads (Invitrogen). Myc-tagged Rad18 was im-
munoprecipitated with Myc antibody (Santa Cruz), and His-tagged
BPLF1 was precipitated with anti-BPLF1 antibody (26). PCNA was de-
tected with PCNA antibody (Santa Cruz Biotechnology), Rad18 was de-
tected with Rad18 antibody (Bethyl Laboratories), Rad6 was detected with
anti-Rad6 antibody (Bethyl Laboratories), and FLAG-tagged ubiquitin
was detected with FLAG M2 antibody (Sigma). Immunoblotting was per-
formed as done previously (26).
BPLF1, PCNA, Ube1, FLAG-ubiquitin, and RAD6/RAD18 purifica-
tion. His-tagged BPLF1 and His-tagged PCNA were purified from Esche-
richia coli as previously described (26). BL21 Codon Plus DE3-RIPL cells
were transformed with the pET22b-Rad6/Rad18 construct. Colonies were
selected on LB agar plates containing 100 g/ml ampicillin. Single colo-
nies were inoculated into 5 ml LB broth containing ampicillin and cul-
tured overnight at 37°C. Overnight preculture was used to inoculate 1 liter
of LB broth at 37°C, cultured to an absorbance of 1.0 at 600 nm, and
induced with isopropyl--D-thiogalactopyranoside (IPTG) with a final
concentration of 0.2 mM Cells were grown for 15 to 17 h at 18°C. Cells
were harvested by centrifugation and lysed by sonication in lysis buffer (50
mM NaH2PO4 [pH 8.0], 300 mM NaCl, 10 mM imidazole, 2 M ZnCl2,
5 mM -mercaptoethanol, and protease inhibitors). Cleared lysate was
incubated with 1 ml nickel-nitrilotriacetic acid (Ni-NTA) resin and fur-
ther purified as described previously (52). Human ubiquitin-activating
enzyme (Ube1) and FLAG-ubiquitin were from R&D Systems.
In vitro competition assay. BPLF1 (10 nM) was incubated with vari-
ous amounts of PCNA (10 to 100 nM) and Rad6/Rad18 (10 to 100 nM) at
room temperature for 2 h and then subjected to immunoprecipitation
with BPLF1 antibody and probed with Rad18, BPLF1, and PCNA anti-
bodies.
In vitro deubiquitination of Rad6. Human Ube1 (100 m) was pre-
incubated with FLAG-ubiquitin (10 M) in ubiquitination buffer (25
mM Tris-HCl [pH 8.0], 150 mM NaCl, 2 M ZnCl2, 10 mM MgCl2, 5 mM
beta-mercaptoethanol [-ME], and 10 mM ATP) at room temperature
for 10 min. Rad6/Rad18 (1 M) and BPLF1 (100 nM) were added, and the
samples were incubated at 30°C for 2 h. Samples were boiled in SDS-
PAGE loading buffer and run on a 12% SDS-PAGE. Western blotting was
performed and probed with FLAG, BPLF1, and Rad6 antibodies.
Immunofluorescence and visualization of yellow fluorescent pro-
tein-tagged Rad18 (YFP-Rad18) foci. Rad18 was cloned into the mono-
meric pEYFP-N1 plasmid, and the construct was confirmed by DNA se-
quencing. H1299 cells were either transfected with pEYFP-N1-Rad18 or
cotransfected with pEYFP-N1-Rad18 and the first 246 N-terminal amino
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acids of BPLF1, FLAG tagged (FLAG-BPLF1 1-246). Twenty-four hours
later, cells were washed with ice-cold phosphate-buffered saline solution
(PBS) and fixed with 4% paraformaldehyde for 5 min. The cells were
washed three times with PBS, permeabilized with 0.1% Triton X-100 at
room temperature for 2 min, and then washed three times with PBS. After
blocking with normal donkey serum at room temperature for 2 h, cells
were probed with primary FLAG antibody (1:1,000; mouse) (clone M2;
Sigma), incubated with Alexa Fluor 594 mouse antibody, stained with
4=,6=-diamidino-2-phenylindole (DAPI), and examined under an Olym-
pus IX 81-ZDC inverted fluorescence microscope (40 magnification).
Wild-type (WT) EBV and BPLF1 knockout cell lines (24, 53) were
used to study Rad18 focus formation under lytic conditions. Cells were
transfected with YFP-Rad18 and the EBV transactivator, BZLF1 (Z), to
induce the lytic phase. Twenty-four hours later, cells were processed as
described above and probed with primary EA-D antibody (1:100; mouse)
to monitor viral induction.
Rad18 siRNA, viral reactivation, infectivity assays, and extracellular
genome copies. Small interfering RNA (siRNA), previously demon-
strated to reduce endogenous protein levels (54, 55), against Rad18, was
purchased from Thermo Fisher. siGENOME nontargeting siRNA no. 1
was used as a control. The 293EBV and 293EBV BPLF1 knockout cell
lines contain a green fluorescent protein (GFP)-tagged viral genome and
were transfected with siRNA twice: 24 h prior to viral induction and at the
time of induction with BZLF1. 293 cells containing the EBV genome
(293EBV) and the BPLF1 knockout cell line (293EBV BPLF1) were
reactivated into the viral replicative cycle by transfection of the viral trans-
activator BZLF1. Upon reactivation, these cells produce the full comple-
ment of EBV lytic genes. Forty-eight hours after lytic induction, superna-
tants and cells were collected for Western blotting, genome copy number
determination, and infectivity studies. For infectivity assays, supernatant
fluids were cleared and placed on Raji cells. Forty-eight and seventy-two
hours after infection, GFP-positive Raji cells were detected by flow cytom-
etry and used as a measure for viral infectivity. Supernatant fluids used for
determining extracellular genome copies were treated with DNase before
DNA extraction using the DNeasy Blood and Tissue kit (Qiagen) to elim-
inate DNA not encapsidated in DNase-resistant viral particles. Extracel-
lular genome copies were determined by real time-PCR as described else-
where, with probes targeting the BamHI repeat region (17).
RESULTS
BPLF1 interacts with Rad18 in cell culture. In previous work, we
demonstrated that BPLF1 physically interacts with and deubiq-
uitinates PCNA and thereby downregulates translesion synthesis
(TLS) (26). In this work, since the balance between ubiquitination
and deubiquitination is a dynamic process, we examined if the E3
ubiquitin ligase, Rad18, responsible for monoubiquitin of PCNA,
could itself be affected by BPLF1. We explored whether BPLF1
inhibits the function of the E2/E3 ubiquitin complex (Rad6/
Rad18) responsible for PCNA ubiquitination and activation of
TLS. Since cellular replication and repair proteins are detected at
sites of EBV replication (38, 39), we explored whether Rad18 is
involved in viral replication and infectivity through its association
with BPLF1. First, to determine if there is physical interaction
between BPLF1 and the Rad6/Rad18 complex, catalytically active
FLAG-tagged BPLF1 1-246 (17) was overexpressed in H1299 cells,
and lysates were immunoprecipitated with FLAG antibody
(Sigma), separated on a 10% SDS-PAGE gel, and probed for en-
dogenous Rad18. Rad18 coprecipitated with FLAG-tagged BPLF1
1-246, thus showing that interaction between BPLF1 1-246 and
Rad18 could occur in cells (Fig. 1A). PCNA served as a positive
control for interaction with BPLF1 (input levels are indicated in
the lower panels of Fig. 1A).
In a reverse immunoprecipitation in which Myc-tagged Rad18
(56) was overexpressed in the presence of BPLF1 1-246 and hem-
agglutinin (HA)-tagged PCNA (57) in H1299 cells, Rad18 was
immunoprecipitated with Myc antibody, and the immunoblot
was probed for BPLF1 (Fig. 1B). BPLF1 was detected only when it
and Myc-tagged Rad18 were coexpressed. Rad6, in addition to
Rad18, was also detected in the immunoprecipitate, which was
expected because physical association of Rad6 with Rad18 is re-
quired for stability of Rad18 (58). The lower panels of Fig. 1 indi-
cate protein levels in lysates. These data demonstrate that BPLF1
interacts with the Rad6/18 complex either directly or through a
complex involving other cellular proteins.
BPLF1 interacts with Rad18 in vitro. We next investigated if
FIG 1 Rad18 interacts with BPLF1 in vivo. (A) H1299 cells were transfected with FLAG-tagged BPLF1 1-246. Lysates were immunoprecipitated (IP) with
anti-FLAG antibody, followed by immunoblotting with FLAG, Rad18, and PCNA antibodies. Whole-cell lysates were also probed to indicate input levels. (B)
Reverse immunoprecipitations were performed to confirm BPLF1 interaction with Rad18. H1299 cells were cotransfected with BPLF1 1-246 and Myc-tagged
Rad18. Immunoprecipitations were performed with Myc antibody, followed by immunoblot analysis with Myc, FLAG, and HA antibodies. Whole-cell lysates
were also probed.
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interactions of Rad6/18 with BPLF1 are direct and independent of
PCNA or are mediated by other cellular factors with the use of
purified proteins in vitro. Since Rad18 is not stable in the absence
of Rad6 (58), both proteins (48) were coexpressed and purified
from E. coli. When purified BPLF1 1-246 (17) and Rad6/18 pro-
tein complex were coincubated, interaction of BPLF1 with both
Rad6 and Rad18 was detected, demonstrating a direct interaction
(Fig. 2A, lanes 1 and 3). PCNA interacted with BPLF1 as expected
and served as a positive control (Fig. 2A, lane 1 and 2). The find-
ings indicate not only that Rad6/18 complex and BPLF1 can in-
teract directly but that the interaction can occur in the absence of
PCNA or other cellular proteins.
PCNA and Rad18 do not compete for binding to BPLF1.
Since BPLF1 interacts with both PCNA and Rad18, we tested
whether there is competition between PCNA and Rad18 for bind-
ing to BPLF1. Competition assays were performed with the con-
centration of BPLF1 held constant and Rad6/18 and PCNA con-
centrations either held constant or adjusted to 10-fold molar
excess. Immunoprecipitations were performed as before (Fig. 2A,
lanes 3 and 4). Molar excess of Rad6/18 did not decrease binding
of PCNA to BPLF1 (Fig. 2A, lanes 2 and 5), nor did excess PCNA
decrease binding of Rad18 to BPLF1 (Fig. 2A, lanes 3 and 4). These
results indicate there is little or no competition between Rad18
and PCNA for binding to BPLF1. Had competition been observed,
binding of the less-dominant partner to BPLF1 1-246 would have
been reduced. Thus, the binding sites on BPLF1 for PCNA, which
binds through the PIP (PCNA-interacting peptide) domain of
BPLF1 (26), and Rad18 are different and function independently.
These results were substantiated by incubating BPLF1 1-246
containing whole-cell lysates from H1299 cells with graduated
amounts of purified PCNA and Rad18 (Fig. 2B). An increase in the
PCNA protein concentration did not affect binding of BPLF1 to
Rad18, nor did an increase in the Rad18 protein concentration
affect binding of BPLF1 to PCNA. Binding of PCNA to BPLF1 was
not detected with a 10 nM concentration of PCNA, but an increase
in the concentration of Rad18 from 10 nM to 20, 50, and 100 nM
enhanced binding of PCNA to BPLF1 (Fig. 2B, compare the top
panel, lane 3, to lanes 6 to 8). Together, these data not only sub-
stantiate the noncompetitive nature of binding of PCNA and
Rad18 to BPLF1 but suggest cooperativity, since increasing Rad18
levels results in increased binding of PCNA to BPLF1.
BPLF1 deubiquitinates Rad6/18 complex. The cascade of en-
zymatic reactions that culminates in ubiquitination of the target
protein proceeds in an ATP-dependent manner. Binding of
BPLF1 with the E2/E3-conjugating and -ligating enzymes (Rad6/
Rad18 complex) offered the opportunity to probe the effects of
BPLF1 deubiquitinating activity on this complex. We incubated
purified Ube1, ubiquitin, and Rad6/Rad18 with or without
BPLF1, used FLAG antibody to detect ubiquitinated products,
and found that Ube1, Rad6, and Rad18 were ubiquitinated when
BPLF1 was absent (Fig. 3A). Addition of purified BPLF1 to the
reaction mixture resulted in deubiquitination of Rad6 and to a
lesser extent Rad18 (Fig. 3A, lanes 3 and 4). Ube1 was not deubiq-
uitinated, suggesting that deubiquitination of Rad6/18 by BPLF1
is specific (Fig. 3A, lanes 1 and 2). These results indicate that func-
tional activity of the Rad6/18 complex is inhibited by BPLF1 and
suggest that all downstream targets of Rad6/18 ubiquitination
would be subsequently inhibited by the enzymatic activity of the
viral DUB.
Results shown in Fig. 3B suggest that BPLF1 partially deubiq-
uitinates Rad18 in vivo. 293EBV cells are a GFP-tagged EBV-
containing cell line in which viral replication can be reactivated by
the EBV immediate early transactivator, BZLF1, to induce the lytic
cycle and produce infectious virus. 293EBV cells were trans-
fected with BPLF1 and BZLF1 as appropriate. When BPLF1 was
expressed, either with or without induction of the lytic cycle, the
amount of the ubiquitinated form (Fig. 3B, upper band) of Rad18
relative to that of the nonubiquitinated form was reduced (Fig. 3B,
compare lane 1 to lane 2 and lane 3 to lane 4). These results suggest
that BPLF1 1-246 partially reduces Rad18 ubiquitination in vivo,
in agreement with in vitro results presented in Fig. 3A. Rad6 ubiq-
uitination was not detected under the in vivo conditions tested.
FIG 2 Rad18 interacts with BPLF1 but does not compete with PCNA for a common binding site on BPLF1. (A) BPLF1 interacts with Rad18 in vitro. BPLF1 and
Rad6/Rad18 protein complex expressed and purified from E. coli were incubated together at equimolar concentrations (lanes 1 to 3) at room temperature for 1
h and then immunoprecipitated with anti-BPLF1 antibody, and Western blots were probed with Rad18, PCNA, and BPLF1 antibodies. Results showed that
BPLF1 interacts with Rad18 independently of PCNA. Additionally, the BPLF1 protein (10 nM) was incubated with either Rad18 (10 nM) and 10-fold excess of
PCNA (100 nM) (lane 4) or PCNA (10 nM) and RAD18 (100 nM) (lane 5) and subjected to immunoprecipitation with BPLF1 antibody. (B) PCNA and Rad18
do not compete for a common binding site on BPLF1. A semi-in vivo assay was used. FLAG-BPLF1 was expressed in H1299 cells, and whole-cell lysates were
incubated with increasing concentrations of purified PCNA and Rad18 at room temperature for 1 h. Reaction mixtures were immunoprecipitated with FLAG
antibody and probed for PCNA, Rad18, and BPLF1. Results indicate no competition between Rad18 and PCNA for BPLF1 binding.
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BPLF1 increases Rad18 focus formation. Normally, Rad18 is
localized to the nucleus and is found in replication foci during the
S phase of the cell cycle (59). To investigate the effect of BPLF1
expression on localization of Rad18, we transiently transfected
H1299 cells with YFP-Rad18 alone or with BPLF1 1-246 and
BPLF1 C61S (Fig. 4). Rad18 when expressed alone localized pre-
dominantly in the nucleus and distributed diffusely, as reported
elsewhere (Fig. 4A) (59, 60). However, when YFP-Rad18 and
BPLF1 were coexpressed, there was relocalization of Rad18 into
distinct nuclear foci in about 85% of cells, compared with 2 to 3%
of cells not expressing BPLF1 (Fig. 4B and D). We observed not
only a BPLF1-dependent increase in formation of Rad18 foci but
also a marked increase in the size of the nucleus in the BPLF1-
expressing cells, in agreement with a previous report (16). When
the active-site mutant of BPLF1 (C61S) was coexpressed with
Rad18, neither Rad18 focus formation nor an increase in nuclear
size was observed (Fig. 4C). We conclude that the enzymatic ac-
tivity is responsible for the formation of Rad18 foci. The Rad18
foci observed are consistent with those seen at cellular replication
forks, which suggests, interestingly, that BPLF1 induces localiza-
tion of Rad18 to sites of active viral replication.
To confirm this important observation, we repeated these ex-
periments with wild-type EBV and BPLF1 knockout cell lines (24,
53). The BPLF1 knockout cell line and virus, generously provided
by Tsurumi and colleagues, was constructed by replacing BPLF1
nucleotides 1 through 975 with neomycin and streptomycin resis-
tance genes, which effectively eliminates the deubiquitinating ac-
tivity contained within its first 205 amino acids (24). Wild-type
and DUB knockout EBV-containing 293 cells were induced into
the viral lytic phase, in which the full complement of lytic genes is
expressed, by transfection with the immediate early EBV transac-
tivator, BZLF1 (Z), along with YFP-Rad18. After 24 h, immuno-
fluorescence studies revealed that 50% of cells contained YFP-
Rad18 nuclear foci (Fig. 5A) in cells in which the early lytic
protein, EA-D, was also detected. The results showed that endog-
enous levels of BPLF1 can induce formation of Rad18 foci (Fig.
5A, upper and middle panels). Upon overexpression of BPLF1 in
reactivated wild-type EBV-containing 293 cells, there was a 90%
increase of YFP-Rad18 foci (Fig. 5A, lower panels). These results
are consistent with those obtained in H1299 cells (Fig. 4). Finally,
complementation experiments were performed with BPLF1
knockout virus. Reactivated BPLF1 knockout virus resulted in vir-
tually no Rad18 focus formation; however, complementation with
exogenously expressed BPLF1 resulted in 90% of cells contain-
ing Rad18 foci (Fig. 5A, middle- and lower-right panels). More-
over, complementation with BPLF1 C61S in BPLF1 knockout cells
resulted in no appreciable increase in cells containing YFP-Rad18
foci (data not shown). Twenty cells under each condition were
examined for the presence of Rad18 foci, and the percentages of
cells containing Rad18 foci are quantitated in Fig. 5B. These data
demonstrate that endogenous levels of BPLF1 can induce Rad18
nuclear focus formation and that functional enzymatic activity of
BPLF1 is required, as well as suggesting that Rad18 localizes to
sites of viral replication during lytic reactivation.
BPLF1 expression increases levels of Rad18. Since BPLF1 in-
teracts with Rad18, we examined whether BPLF1 could affect
Rad18 protein levels. 293EBV cells were transfected with BPLF1,
and total lysates were probed for endogenous levels of Rad18.
Overexpression of BPLF1 resulted in increased levels of Rad18
(Fig. 6A) whether or not the lytic cycle was induced with BZLF1
(top panel, lanes 2 and 4). These results indicate that BPLF1 reg-
ulates Rad18 levels. Interestingly, Rad6 levels remained largely
unchanged. We also investigated protein levels in 293T cells (Fig.
6B) and again observed that the presence of functional BPLF1
resulted in increased Rad18 levels; however, enzymatically inac-
tive BPLF1 C61S did not increase Rad18 levels. These results sug-
gest that BPLF1 indirectly affects Rad18 protein levels through its
deubiquitinating activity, either by stabilizing Rad18 or by in-
creasing its expression.
To determine if upregulation of Rad18 protein levels is impor-
tant during viral replication, 293EBV cells, which express
the full complement of lytic proteins upon reactivation, and
293EBV BPLF1 KO cells, where the sequence encoding the N-
terminal region of BPLF1 was deleted (generous gift of T. Tsu-
rumi) (24), were induced with the viral lytic transactivator BZLF1.
Endogenous levels of BPLF1 expressed during EBV lytic replica-
FIG 3 BPLF1 deubiquitinates the Rad6/Rad18 complex. (A) BPLF1 deubiq-
uitinates Rad6/18 in vitro. Ube1 was incubated with Rad6/Rad18 and FLAG-
ubiquitin in the presence or absence of BPLF1. Samples were run on a 12%
SDS-PAGE gel, immunoblotted, and probed with FLAG, Rad18, and BPLF1
antibody. BPLF1 specifically deubiquitinates Rad6 but not Ube1. Slight deu-
biquitination of Rad18 was also observed. Input levels are shown at the bot-
tom. (B) Rad18 is likely deubiquitinated by BPLF1 in vivo. 293EBV cells
were transfected with BPLF1 1-246 and BZLF1 (to induce lytic replication)
where indicated. The upper band in the Rad18 panel is consistent with the
monoubiquitinated form of Rad18 and appears to be reduced in the pres-
ence of BPLF1. BPLF1 and GAPDH loading controls are shown in the
middle and bottom panels.
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tion keep protein levels of Rad18 high during viral reactivation
(Fig. 6C). Upon reactivation of WT virus, Rad18 levels remained
fairly constant in relation to cellular glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) protein levels. However, induction of
the EBV BPLF1 KO virus decreased levels of the Rad18 protein by
approximately 50% (Fig. 6C, upper panels). The graphs below the
blots show the relative Rad18 protein levels when normalized to
GAPDH levels in the cell lysates. These data suggest that endoge-
nous levels of BPLF1 are sufficient and perhaps necessary to main-
tain high levels of Rad18 during induction of WT virus, which
would otherwise be reduced in the absence of BPLF1. Miyase et al.
(61) showed that Rad18 polyubiquitination could direct its deg-
radation by the proteasome in vitro, which suggests that the in-
crease in Rad18 levels could be due to rescue of Rad18 by BPLF1
from proteasomal degradation; however, in our studies, we did
not detect polyubiquitinated forms of Rad18.
Silencing of endogenous Rad18 by siRNA does not affect ex-
tracellular genome copy number. Finally, the effects of Rad18 on
viral replication and infectivity were investigated by transfecting
293EBV cells with siRNA against Rad18 24 h prior to induction
of the lytic cycle. Forty-eight hours after induction, supernatant
fluids were collected, cleared, and used for determination of the
number of extracellular genome copies. EBV infectious units were
assayed by infection of Raji cells (62). Before extraction of DNA
from supernatant fluids, samples were treated with DNase to elim-
inate nonencapsidated DNA. EBV particles are DNase resistant,
and extracellular genome copy numbers represent viral genomes
packaged into virions. The cell pellet was also collected and used
for Western blotting. Levels of extracellular EBV genome copies
were similar when Rad18 levels were reduced with siRNA (Fig.
7A). It should be noted that cellular DNA replication is halted
upon induction of the EBV lytic cycle, so that effects on cellular
DNA should be negligible, and the observed effects are likely to be
specific to viral replication processes and production of viral ge-
nomes.
Rad18 is necessary for efficient production of infectious vi-
rus. To assay for viral infectivity, Raji cells were inoculated with
supernatant fluids containing EBV virions from 293EBV cells
treated with control or Rad18 siRNA, and infection continued for
48 and 72 h. Infectivity was measured by detection of GFP-tagged
EBV genomes in Raji cells by flow cytometry. Figure 7B shows that
reduction of Rad18 protein levels by siRNA decreases viral infec-
tivity both at 48 and 72 h after infection. While the amounts of
genome-containing DNase-resistant EBV particles released into
the supernatant fluid from siRNA Rad18-treated and untreated
cell lines are similar, approximately 50% fewer virions produced
from the siRNA Rad18-treated cell lines were infectious. This re-
sult suggests that viral genome copies, which are still produced in
FIG 4 Expression of BPLF1 increases Rad18 focus formation. Two separate fields of view are shown for each condition (left panels versus right panels [A-C]).
(A) H1299 cells transfected with YFP-Rad18 are homogeneously distributed and are localized primarily in the nucleus. (B) H1299 cells coexpressing the inactive
BPLF1 C61S and YFP-Rad18 do not affect focus formation. (C) H1299 cells coexpressing FLAG-BPLF1 and YFP-Rad18 show increased nuclear focus formation
of Rad18. (D) Quantification of percentages of cells with focus formation in panels A, B, and C. One hundred cells were counted for each sample.
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similar numbers and are encapsidated and egress efficiently as
DNase-resistant viral particles, may contain damaged viral DNA
due to the loss of Rad18 and result in decreased infectivity. Effi-
cient knockdown of Rad18 was achieved with siRNA, and protein
levels of Rad6 were largely independent of Rad18 levels (Fig. 7C).
The data demonstrate that Rad18 has a significant impact on EBV
infectivity.
Rad 18 overexpression partially restores loss of infectivity of
the DUB activity knockout virus. Since knockdown of Rad18
resulted in decreased WT EBV infectivity and the presence of
BPLF1 increases Rad18 protein levels and focus formation, we
investigated if overexpression of Rad18 could overcome deficien-
cies in infectivity observed with the BPLF1 knockout virus (24)
(Fig. 7D). Cells containing the EBV BPLF1 knockout virus were
induced with the viral transactivator BZLF1 alone or in the pres-
ence of exogenously supplied Rad18 or BPLF1. Figure 7D reveals
that complementation with exogenous Rad18 during the produc-
tive cycle of the knockout virus increased infectious virus produc-
tion by approximately 50%, a result that is quite consistent with
the decrease in infectivity produced with knockdown of Rad18
with siRNA (Fig. 7B). Exogenous expression of BPLF1 resulted in
similar levels of infectious titer rescue at 48 h and a marked further
FIG 5 Endogenous BPLF1 expression induces Rad18 focus formation. (A) 293EBV WT and 293EBV BPLF1 knockout cell lines were transfected with
YFP-Rad18 (upper panels), additionally transfected with BZLF1 to induce lytic replication (middle panels), and induced and supplied with BPLF1 exogenously
(lower panels). Induction of WT virus produced Rad18 foci but not BPLF1 knockout virus. Cell lines containing the EBV genomes are GFP tagged. EA-D (red)
is an early lytic gene and demonstrates viral reactivation. (B) Quantitation of cells containing Rad18 foci. Twenty cells under each condition were examined for
the presence of Rad18 foci.
FIG 6 BPLF1 expression increases Rad18 protein levels. (A) 293EBV cells were transfected with BPLF1 1-246, and the lytic cycle was induced with BZLF1.
Immunoblotting revealed a substantial increase in Rad18 protein levels when BPLF1 was expressed. Rad6 levels remained largely unchanged. EA-D is an EBV
early protein that indicates induction of the lytic program. (B) 293T cells were transfected with functional (BPLF1 1-246) or nonfunctional (BPLF1 C61S) BPLF1.
Rad18 levels were increased only in the presence of functional BPLF1. (C) Induction of BPLF1 knockout virus results in less Rad18 protein levels than with the
WT. WT and BPLF1 knockout viruses were induced into the lytic replication cycle by transfection of BZLF1. Levels of Rad18 were normalized to GAPDH protein
levels.
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restoration of infectious titer at 72 h. These data illustrate that
Rad18, through its interaction and regulation by BPLF1, partially
compensates for deficiencies in infectivity produced by the loss of
BPLF1 expression and further demonstrate that Rad18 enhances
viral infectivity. The results identify an important and previously
unknown role of the Rad6/18 complex in EBV replication and
infectivity.
DISCUSSION
Deletion of conserved herpesvirus deubiquitinating genes or dis-
ruption of the catalytic triad results in a reduction of either viral
genome copies or infectivity by approximately 90% (17, 20–24).
The importance of BPLF1 during EBV infection is expanding as
more of its targets and functional effects are discovered. The only
viral target discovered to date for BPLF1 is the EBV ribonucleotide
reductase (RR), in which deubiquitination of its large subunit
results in a decrease of RR activity (17). In addition to PCNA,
TRAF6 and cullin ring ligases have now been identified as cellular
targets for BPLF1 (16, 24, 28).
Additionally, reactivation of EBV lytic replication elicits a cel-
lular DNA damage response, specifically the ataxia telangiectasia-
mutated (ATM) pathway (63, 64), which in part may be regulated
by BPLF1 (26). The effects of BPLF1 on cellular DNA repair pro-
cesses are significant. We demonstrated previously that BPLF1
aborts TLS repair by deubiquitinating the monoubiquitinated
form of PCNA, which initiates DNA repair and results in a sharp
decrease in recruitment of the repair polymerase, pol eta, to sites
of cellular DNA damage (26). We hypothesized that these repair
factors may also be involved in viral replication.
In this report, we examine another DNA repair factor, Rad18,
which is responsible for monoubiquitinating PCNA and activat-
ing TLS, following observations that there was a modest increase
in Rad18 levels when BPLF1 was overexpressed under conditions
that damage DNA. We first evaluated effects of BPLF1 on Rad18
and then investigated Rad18’s subsequent effects on infectivity in
the absence of exogenously induced DNA damage.
We found that BPLF1 interacts physically with endogenous
levels of Rad18 in vivo. However, since Rad18 and PCNA both
interact with BPLF1, we then examined if the interaction between
the Rad18 and BPLF1 proteins was direct with the use of purified
proteins in vitro. These studies demonstrated that BPLF1 and
Rad18 can interact directly, that the interaction is not dependent
on the presence of PCNA, and that Rad18 must not compete with
PCNA for binding to the conserved PIP (PCNA-interacting pep-
tide) site (26) on BPLF1, since increasing the amounts of either
Rad18 or PCNA did not inhibit binding of either protein to
BPLF1. Conversely, when BPLF1-containing lysates were incu-
bated with increasing concentrations of PCNA, an increase in
Rad18 binding to BPLF1 was detected (Fig. 2B). Neither binding
of PCNA nor Rad18 to BPLF1 was detected under conditions of
short exposure when both Rad18 and PCNA were held at 10 nM
concentrations. However, when Rad18 concentrations were in-
creased to 20, 50, and 100 nM, binding of PCNA to BPLF1 in-
creased, suggesting that some level of cooperativity may occur.
FIG 7 Rad18 levels contribute to viral infectivity. Knockdown of Rad18 levels with siRNA reduces viral infectivity (A to C). (A) Extracellular genome copies.
293EBV cells were treated with siRNA against Rad18 and induced with BZLF1 for 48 h. DNA was extracted from supernatant fluids, and genome copies were
detected with quantitative PCR (qPCR) targeting the BamHI repeat region. (B) Viral infectivity. The same supernatant fluids collected for assay of extracellular
genome copy number were assayed for infectious titer on Raji cells. Infectivity was determined with flow cytometry 48 and 72 h after infection. (C) Immunoblots
showing knockdown of Rad18. (D) Viral infectivity of BPLF1 knockout virus is partially restored by overexpression of Rad18. BPLF1 knockout virus was induced
with Z and assayed for infectivity on Raji cells. Rad18 and BPLF1 were overexpressed as indicated. Experiments were performed in triplicate, and error bars
represent the standard errors of means.
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Conversely, increased levels of PCNA did not result in increased
binding of Rad18 to BPLF1.
The in vitro ubiquitination/deubiquitination experiments uti-
lizing the E1-activating enzyme, Ube1, and the Rad6/18 E2- and
E3-conjugating and ligating enzymes, respectively, demonstrated
that the Rad6/18 complex, which is autoubiquitinated, is deubiq-
uitinated by BPLF1. The deubiquitination of Rad6/18 appears to
be specific, since the ubiquitinated form of Ube1 was not affected
by BPLF1. While Rad18 was only partially deubiquitinated under
the conditions tested, Rad6 was almost completely deubiquiti-
nated. This is significant because the ubiquitin covalently linked to
the active site of Rad6 is transferred by Rad18 to the target protein.
In this manner, BPLF1 can inhibit PCNA ubiquitination by strip-
ping the ubiquitin from the E2-conjugating enzyme, thereby mak-
ing it unavailable for transfer to PCNA. These findings suggest a
new mechanism by which BPLF1 can inhibit TLS, in addition to
its inhibition by direct deubiquitination of PCNA, which we re-
ported previously.
Apart from TLS, additional targets of Rad6 activity may be
regulated by BPLF1’s ability to remove monoubiquitin from
Rad6. Rad6 can directly ubiquitinate substrates and regulate im-
portant cellular processes in the absence of Rad18. Rad6 is highly
conserved in eukaryotic evolution and has two isoforms with ap-
proximately 95% identity, Rad6A and Rad6B (26). There is a re-
quirement for at least one functional form in somatic cell types
(65). Rad6 is responsible for ubiquitinating the histones H2A and
H2B, as well as -catenin, resulting in -catenin stabilization in
the absence of E3 ubiquitin ligases (66–69). Rad6 also forms a
complex with p53 and p14ARF, both tumor suppressor genes,
and mediates ubiquitination of p53 (70). Our finding of deu-
biquitination of Rad6 by BPLF1 introduces these targets of
Rad6 activity as new avenues for study, and we are now begin-
ning to explore the effects of BPLF1 deubiquitination of Rad6
on histone modification.
We also showed that BPLF1 expression caused relocalization of
Rad18 to discrete nuclear foci, that the focus formation was de-
pendent on enzymatically active BPLF1, and that endogenous lev-
els of BPLF1 were sufficient to induce Rad18 focus formation This
result is in agreement with published data that Rad18 foci are
formed during S phase and is relevant because BPLF1 induces an
S-phase-like state which results in increased nuclear size and DNA
content (16). We also demonstrate that the presence of functional
BPLF1 results in increased levels of Rad18 (Fig. 6). Significant
changes in Rad18 protein levels have been observed during cell
cycle progression, with levels highest during S phase (54). These
results would be consistent with BPLF1 inducing an S-phase-like
environment favorable for viral replication. Rad18 mRNA levels
were found to fluctuate during cell cycle progression as well (60).
Here we have shown that protein levels of Rad18 are clearly
increased in the presence of BPLF1, and endogenous levels them-
selves contribute to increased Rad18 expression. The data show
that viral reactivation in the absence of BPLF1 utilizing the BPLF1
knockout virus results in decreased Rad18 protein levels. How-
ever, when BPLF1 is expressed endogenously in the context of WT
virus, Rad18 protein levels remain high, suggesting that high levels
of Rad18 are important for EBV replication. BPLF1 may influence
Rad18 protein levels by contributing to its stability or by upregu-
lation of transcriptional or translational activities or both. The
E2F family of transcription factors is activated by a variety of in-
tracellular and extracellular signals, and E2F levels increase as EBV
lytic replication proceeds (64, 71). E2F3 associates with the Rad18
promoter and regulates its activity (71), and perhaps BPLF1 af-
fects this activity during EBV infection.
Last, we have demonstrated that Rad18 is important for viral
infectivity. Knockdown of Rad18 did not significantly reduce the
number of extracellular genome copies; however, infectivity was
significantly decreased, by 50%. Additionally, a decrease in pro-
duction of infectious virus by reactivation of BPLF1 knockout
virus could be partially restored by overexpression of Rad18. This
result confirms the idea that Rad18 is indeed utilized by the virus
for efficient replication of functional virus and that the levels of
Rad18 are upregulated and maintained during lytic infection by
BPLF1. The mechanism by which Rad18 levels are regulated is
currently unclear and will require additional investigation, but the
enzymatic function of BPLF1 seems to be required to maintain
high levels of Rad18.
EBV itself is not known to encode genes necessary to repair
viral DNA damage arising during lytic replication. Cellular repair
factors, such as Rad18 and PCNA, may be necessary to maintain
the integrity of viral DNA. If Rad18 does function to repair viral
DNA damage, extracellular genomes released in its absence may
contain more DNA errors and therefore lead to the decrease in
infectious particles. Errors in viral DNA may contribute to faulty
translation of proteins that are required for entry and establish-
ment of a second round of replication. Results showing that infec-
tivity is decreased by 50% when Rad18 is suppressed indicate
that it is not strictly required yet is important for viral infectivity.
This partial decrease in infectivity may be explained in that only a
fraction of viral genomes are substantially damaged during nor-
mal replication. Future studies have been designed to evaluate the
incidence of damage to EBV DNA during lytic replication. These
studies are significant in that DNA damage is a major contributor
to genetic instability, and they may provide evidence that BPLF1
deubiquitinating activity contributes to the tumorigenic proper-
ties of EBV.
Previously we showed that BPLF1 deubiquitinates PCNA and
is inhibitory for TLS, and yet now we suggest that BPLF1 promotes
an increase in Rad18 protein levels, which would be expected to
stimulate TLS under DNA-damaging conditions. While these
findings appear to be paradoxical, EBV may utilize these TLS fac-
tors in a nonclassical fashion for viral replication, and in addition,
Rad18 also contributes to other effector pathways besides TLS. In
our previous study, UV exposure largely shifted the function of
Rad18 to activation of TLS, which would likely not be activated so
strongly in the course of normal infection. Perhaps, therefore,
BPLF1 shuts off TLS via PCNA deubiquitination under induced
damage conditions yet promotes Rad18 stability and expression
under infectious conditions, thereby contributing to ubiquitina-
tion of other Rad18 substrates, perhaps viral, and providing for an
environment advantageous for viral replication and efficient pro-
duction of infectious virus. It is not unusual for a deubiquitinating
enzyme to target an E3 ligase, which could serve as a means of
regulating the function of target proteins in a cell cycle-dependent
fashion (72–75).
Exposure of latently EBV-infected cells to DNA damage stim-
uli, including chemotherapy and irradiation, can reactivate viral
replication and induce the lytic cycle (76, 77). Induction of EBV
lytic replication elicits a DNA damage response, specifically, acti-
vation of the ataxia telangiectasia-mutated (ATM) signal trans-
duction pathway (64), which plays a key role in phosphorylating
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and activating DNA damage effectors, p53, H2AX, and CHK2
(64, 78, 79). Additionally, the Kenney lab showed that ATM is
involved in promoting EBV lytic reactivation (63). Knockdown
of ATM inhibited EBV reactivation, and conversely, activation
of ATM with Nutlin-3 increased lytic reactivation. Kulinski et
al. demonstrated that chronic mouse gammaherpesvirus 68
(MHV68) infection is poorly controlled in mice that have insuffi-
cient ATM levels, suggesting that ATM is necessary for adaptive
immune responses against this gammaherpesvirus (80). Nikitin et
al. found that the DNA damage response is involved in tumor
suppressor function: inhibition of ATM and Chk2 increased the
transformation efficiency of EBV in primary B cells (81). Addi-
tionally, the EBV latency proteins LMP1, EBNA1, and EBNA3C
also inhibit the DNA damage response (82, 83) but are not ex-
pected to affect viral replication. In summary, we report that the
EBV lytic cycle protein BPLF1 mediates Rad18 function, and we
have demonstrated the necessity for Rad18 for efficient produc-
tion of infectious virus. BPLF1’s deubiquitinating function may be
a mechanism by which EBV co-opts cellular repair and replication
factors in maintaining the fidelity of viral replication.
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